Clemmer James C

SEC source: 0001567619-21-015951 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 50,139 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.exercise_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

F3 · derivative.expiration_date: On October 16, 2019, the reporting person received a target grant of 50,139 performance share units. Between 0% and 200% of the target number was to be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Based on performance over the period, 2,395 shares of Common Stock were issued to the reporting person under this grant and the remaining performance share units were forfeited.

SEC source: 0001567619-21-015951 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 369,533

F2 · shares: The exempt disposition of 9,021 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-015951 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,554

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 19,387 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on October 16, 2019.

SEC source: 0001567619-21-016023 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 34,938 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.exercise_date: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

F4 · derivative.expiration_date: On July 18, 2018, the reporting person received a target grant of 34,938 performance share units. Between 0% and 200% of the target number was to be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Based on performance over the period, 40,528 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-21-016023 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 378,163

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F3 · shares: The exempt disposition of 21,532 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-016023 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 399,695

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · security: On August 17, 2021, the reporting person filed a Form 4 to report the vesting and settlement of performance share units and the sale of certain underlying shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), which contained administrative errors as to the terms of the performance share units and the number of shares of Common Stock of the Company issued and sold.

F2 · shares: This acquisition of 40,528 shares of Common Stock of the Company represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-014055 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 359,167

F1 · shares: The exempt disposition of 2,105 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-21-013917 · doc1.xml · derivative · entry 6

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,154

Underlying: Common Stock · 71,154 shares

Expires 2031-07-21

F6 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013917 · doc1.xml · derivative · entry 5

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,378

Underlying: Common Stock · 52,378 shares

Expires not disclosed

F5 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F5 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 361,272

F4 · shares: The acquisition of 26,189 shares of Common Stock of the Company represents 26,189 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-022713 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 101,667

Underlying: Common Stock · 101,667 shares

Expires 2031-07-21

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F4 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 21, 2022, such that 25% of the options will vest on each of July 21, 2022, 2023, 2024 and 2025.

F1 · derivative.underlying_shares: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F1 · balance_after: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

SEC source: 0001567619-21-022713 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 74,840

Underlying: Common Stock · 74,840 shares

Expires not disclosed

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period (with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate)) in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.underlying_shares: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F1 · balance_after: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

SEC source: 0001567619-21-022713 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 372,503

F1 · security: On July 23, 2021, the reporting person filed a Form 4 to report the acquisition and granting of shares of restricted stock units, performance rights and stock options of AngioDynamics, Inc. (the "Company") which contained administrative errors as to the number of restricted stock units, performance rights and stock options granted and the exercise price of such options.

F2 · shares: The acquisition of 37,420 shares of common stock ("Common Stock") of the Company represents 37,420 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 21, 2022, such that 25% of the restricted stock units will vest on each of July 21, 2022, 2023, 2024 and 2025.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 335,083

F3 · shares: The exempt disposition of 1,483 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,566

F2 · shares: The exempt disposition of 2,131 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-21-013917 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 338,697

F1 · shares: The exempt disposition of 4,622 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 14, 2020.

SEC source: 0001567619-20-014068 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 343,319

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $8.24 to $8.26, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-20-013825 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 303,319

F2 · shares: The exempt disposition of 1,799 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-20-013825 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 305,118

F1 · shares: The exempt disposition of 1,876 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-20-013546 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 306,994

F2 · shares: The exempt disposition of 1,483 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-20-013546 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 308,477

F1 · shares: The exempt disposition of 2,131 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 17, 2019.

SEC source: 0001567619-20-013438 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 160,237

Underlying: Common Stock · 160,237 shares

Expires 2030-07-14

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 14, 2021, such that 25% of the options will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-013438 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 108,871

Underlying: Common Stock · 108,871 shares

Expires not disclosed

F2 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

F2 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period in accordance with performance metrics as determined by the compensation committee. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-20-013438 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 310,608

F1 · shares: This acquisition of 54,435 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 54,435 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 14, 2021, such that 25% of the restricted stock units will vest on each of July 14, 2021, 2022, 2023 and 2024.

SEC source: 0001567619-20-007647 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,173

F1 · shares: The exempt disposition of 4,245 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 4, 2016.

SEC source: 0000899243-20-007207 · doc4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,082

SEC source: 0001567619-19-020025 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 260,418

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.15 to $14.22, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote 1.

SEC source: 0001567619-19-019773 · doc1.xml · derivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,139

Underlying: Common Stock · 50,139 shares

Expires not disclosed

F1 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

F1 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of common stock ("Common Stock") of AngioDynamics, Inc. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based equally on revenue growth and adjusted earnings per share growth over a three-year performance period with a potential upward or downward 20% adjustment on the calculated achievement based on total shareholder return relative to a peer group of companies over a three-year performance period (for a total potential payout of up to 240% of the target number in the aggregate). Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001567619-19-015724 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,558

F2 · shares: The exempt disposition of 1,752 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001567619-19-015724 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 143,310

F1 · shares: The exempt disposition of 1,826 shares of common stock of AngioDynamics, Inc. ("Common Stock") was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001567619-19-015209 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 145,136

F1 · shares: The exempt disposition of 1,444 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 18, 2018.

SEC source: 0001567619-19-015039 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 83,967

Underlying: Common Stock · 83,967 shares

Expires 2029-07-17

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 17, 2020, such that 25% of the options will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-015039 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,580

F1 · shares: This acquisition of 25,104 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 25,104 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 17, 2020, such that 25% of the restricted stock units will vest on each of July 17, 2020, 2021, 2022 and 2023.

SEC source: 0001567619-19-017316 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 250,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.exercise_date: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant.

F3 · derivative.expiration_date: On April 1, 2016, the reporting person received a target grant of 250,000 performance share units vesting between 0% and 200%. The performance of this award was based on the Company's total shareholder return relative to a peer group of companies over a three-year period covering the Company's fiscal years 2017, 2018 and 2019. Based on the Company's performance over this period, 200,000 shares of Common Stock were issued to the reporting person under this grant.

SEC source: 0001567619-19-017316 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 245,418

F2 · shares: The exempt disposition of 96,140 shares of Common Stock of the Company was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying performance share units granted to the reporting person on April 1, 2016.

SEC source: 0001567619-19-017316 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 341,558

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: This acquisition of 200,000 shares of common stock ("Common Stock") of AngioDynamics, Inc. (the "Company"), represents shares acquired through the vesting and settlement of performance share units granted to the reporting person on April 1, 2016.

SEC source: 0001567619-19-008523 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,476

F1 · shares: The exempt disposition of 4,232 shares of common stock of AngioDynamics, Inc. was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on April 4, 2016.

SEC source: 0000899243-19-005209 · doc4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,987

SEC source: 0001140361-18-034274 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 125,708

F1 · shares: The exempt disposition of 1,752 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-18-033942 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,460

F1 · shares: The exempt disposition of 1,826 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 26, 2017.

SEC source: 0001140361-18-033093 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,938

Underlying: Common Stock · 34,938 shares

Expires not disclosed

F3 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

F3 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2021. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-18-033093 · doc1.xml · derivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,651

Underlying: Common Stock · 55,651 shares

Expires 2028-07-18

F2 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 18, 2019, such that 25% of the options will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0001140361-18-033093 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 129,286

F1 · shares: This acquisition of 17,469 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 17,469 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 18, 2019, such that 25% of the restricted stock units will vest on each of July 18, 2019, 2020, 2021 and 2022.

SEC source: 0000899243-18-006651 · doc4.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,634

SEC source: 0001140361-17-029179 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 111,817

F2 · shares: The exempt disposition of 1,958 shares of Common Stock was made to satisfy tax withholding obligations in connection with the pre-determined vesting of shares underlying restricted stock units granted to the reporting person on July 27, 2016.

SEC source: 0001140361-17-029179 · doc1.xml · derivative · entry 4

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,184

Underlying: Common Stock · 44,184 shares

Expires not disclosed

F4 · derivative.exercise_price: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.exercise_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

F4 · derivative.expiration_date: Each performance right represents a contingent right to receive one share of Common Stock. The target number of shares of Common Stock is set forth in columns 5 and 7 of Table II. Between 0% and 200% of the target number will be earned based on total shareholder return relative to a peer group of companies over a three-year performance period ending May 31, 2020. Any shares that do not vest at the end of the performance period will be forfeited.

SEC source: 0001140361-17-029179 · doc1.xml · derivative · entry 3

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 77,627

Underlying: Common Stock · 77,627 shares

Expires 2027-07-26

F3 · derivative.exercise_date: These stock options vest in four equal annual installments beginning on July 26, 2018, such that 25% of the options will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-029179 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 113,775

F1 · shares: This acquisition of 22,092 shares of common stock ("Common Stock") of AngioDynamics, Inc. represents 22,092 restricted stock units, each of which represents a contingent right to receive one share of Common Stock. These restricted stock units vest in four equal annual installments beginning on July 26, 2018, such that 25% of the restricted stock units will vest on each of July 26, 2018, 2019, 2020 and 2021.

SEC source: 0001140361-17-028409 · doc1.xml · nonDerivative · entry 2

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 91,683

SEC source: 0001140361-17-028409 · doc1.xml · nonDerivative · entry 1

Clemmer James C · CIK 0001476700 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 86,683

F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $15.54 to $15.70, inclusive. The reporting person has provided to AngioDynamics, Inc., and undertakes to provide to any security holder of AngioDynamics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote 1.